Lu-177 HA-DOTATATE for Peptide Receptor Radionuclide Therapy (PRRT): First Results in Patients Concerning Biodistribution, Normal Organ and Tumor Dosimetry

被引：0
|
作者：
Schuchardt, C. [1 ]
Kulkarni, H. R. [1 ]
Wiessalla, S. [1 ]
Shahinfar, M. [1 ]
Shafaei, S. [1 ]
Kropf, S. [2 ]
Wester, H. J. [3 ,4 ]
Baum, R. P. [1 ]
机构：
[1] Zent Klin Bad Berka GmbH, THERANOST Ctr Mol Radiotherapy & Mol Imaging, Bad Berka, Germany
[2] Scintomics GmbH, Fuerstenfeldbruck, Germany
[3] Tech Univ Munich, Fac Chem, D-80290 Munich, Germany
[4] Tech Univ Munich, Fac Med, D-80290 Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP290
引用
收藏
页码：S224 / S224
页数：1
相关论文
共 50 条
  • [31] Evaluation of different infusion protocols and dosimetry assessment in patients undergoing peptide receptor radionuclide therapy with 177Lu-DOTATATE
    Varallo, A.
    Piscopo, L.
    Gaudieri, V.
    Grasso, S.
    Zampella, E.
    Nappi, C.
    Oliviero, C.
    Italiano, M.
    Volpe, F.
    Falzarano, M.
    Clemente, S.
    Cuocolo, A.
    Klain, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S649 - S649
  • [32] Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
    Alsadik, Shahad
    Gnanasegaran, Gopinath
    Chen, Luohai
    Mandair, Dalvinder
    Toumpanakis, Christos
    Caplin, Martyn
    Navalkissoor, Shaunak
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (10) : 1503 - 1508
  • [33] Mixed model time-activity fitting to reduce SPECT/CT imaging time points for dosimetry in Lu-177 peptide receptor radionuclide therapy (PRRT)
    Devasia, Theresa
    Dewaraja, Yuni
    Schipper, Matthew
    Wong, Ka Kit
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [34] Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC
    Sierra, Maribel L.
    Agazzi, Alberto
    Bodei, Lisa
    Pacifici, Monica
    Arico, Demetrio
    De Cicco, Concetta
    Quarna, Jessica
    Sansovini, Maddalena
    De Simone, Michele
    Paganelli, Giovanni
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2009, 24 (06) : 659 - 665
  • [35] Impaired kidney function is associated with higher absorbed dose to organ-at-risk (OAR) in177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT)
    Marin, G.
    Levillain, H.
    Karfis, I.
    Reynaert, N.
    Vandenberghe, S.
    Vanderlinden, B.
    Flamen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S595 - S595
  • [36] Comparison of Lu-177 obtained from two different commercial vendors for peptide receptor radionuclide therapy of neuroendocrine tumor patients: Preliminary results
    Lehmann, C.
    Prasad, V.
    Schuchardt, C.
    Mueller, D.
    Zachert, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S440 - S440
  • [37] Peptide Receptor Radionuclide Therapy using SSTR antagonists: biokinetics and dosimetry of Lu-177 DOTA-LM3
    Schuchardt, C.
    Wiessalla, S.
    Singh, A.
    Zhang, J.
    Kulkarni, H. R.
    Mueller, D.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S90 - S90
  • [38] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)
    Navarro Martin, M.
    Teran Brage, E.
    Campana-Diaz, E.
    Garcia-Talavera, P.
    Reguera Puertas, P.
    Rama-Alonso, S.
    Garijo-Martinez, M. C.
    Felix, L. C.
    Diaz Sanchez, P.
    Vidal Tocino, R.
    Fonseca Sanchez, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
  • [39] First-In-Human Experience of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Patients with Advanced Multiple Myeloma
    Delbart, W.
    Karfis, I.
    Vercruyssen, M.
    Vercauteren, S.
    Wimana, Z.
    Meuleman, N.
    Flamen, P.
    Woff, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S250 - S251
  • [40] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Swiha, Mina M.
    Sutherland, Duncan E. K.
    Sistani, Golmehr
    Khatami, Alireza
    Abazid, Rami M.
    Mujoomdar, Amol
    Wiseman, Daniele P.
    Romsa, Jonathan G.
    Reid, Robert H.
    Laidley, David T.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 225 - 236
12345